NLRP3 INHIBITOR
For the trader and investor in you: A collection of stocks suitable for trading and investing alike
It is probably times like these, where valuations are high and the desire to trade and invest is also at a peak, one needs to set some rules, both for investing and trading. As a first step, have a well defined set of stocks, where one would invest and trade. So, that one does stray into stocks which are moving up just because there is sunshine all over the street. This might appear conservative to some as it limits the scope but being conservative is a way of bringing in discipline, especially when it comes to trading. So, out of a total universe of more than 3000 stocks, how about having a set of 50 non - nifty stocks which increase the probability of you making money both in volatile and trending markets and also satisfy your desire to be a trader and investor at same time.
More than just an index and it's not Nifty: A collection of stocks suitable for trading and investing alike
Out of 50 stocks, only 5 of them have delivered negative returns in the last one year. Out of these 5 stocks, three stocks belong to one industrial house which faced headwinds early last year. 7 stocks have delivered more than 100 percent return, 4 stocks have gained between 80 to 100 %, 8 stocks have gained between 60 to 80 %, 5 stocks between 40 to 60 %, 12 stocks have gained between 20 to 40% and 9 stocks have gained between 0 to 20%. So, if you have focussed only on these 50 stocks out of a total universe of more than 3000 stocks which are traded, the probability that you would have been able to make money both in volatile and trending markets and also satisfy your desire to be a trader and investor at same time would have been met. The reason why is stocks? Most retail traders have a tendency to trade with bullish bias and prefer taking long positions rather than going short even when markets are not so bullish.
Probability favors them: A set of stocks to fulfill the desire of trader and investor in you
Trading and investing are very different both in terms of skill sets, requirement of capital and finally the returns which one is able to generate from each of them. That is probably the reason that even the most exceptional wealth creators in the world have accepted this fact and stayed with what they are good at, either investing or trading. But the majority of us have this desire to do both trading and investing at the same time. This mixing of both may lead to a situation where either there would be no returns, or sub optima returns. While in the stock market there is nothing called guaranteed but there is a set of stocks which have higher probability to help all those who want to be trader and investor at both the time.
Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian pharma companies have come a long way.
Desire management, the quantitative way: A set of stocks for those who wish to do trade and invest at the same time
Out of 50 stocks, only 7 have delivered negative returns in the last one year. Out of these 7 stocks, four stocks belong to one industrial house which faced headwinds at the start of 2023. 6 stocks have delivered more than 100 percent return and 26 stocks have gained more than 20 % in the last one year. If you had focussed only on these set stocks and either invested or only traded in them only, the possibility of being able to satisfy your desire to be a trader and investor at same time would have been met.
Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%
The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might appear to be a sudden up move, if one looks at what has happened in the pharma sector in the last eight years, there is a good chance that right from valuation readjustments to changing business model might play a role bringing the large pharma companies back into limelight. Infact some of these stocks have quietly inched upward in the last few months. It might be too early to call, but if a re-rating plays out in this space, it might surprise many in terms of price movement.
- Go To Page 1
Good for all market conditions: 6 largecap stocks with right mix of RoE & RoCE
There is sunshine all around, better than expected GDP numbers, further decline in oil prices, falling US bond yields and clear indication from RBI that it is in no mood to increase interest rates any further. So while macros are bullish and could not get better, it is time to spend some time in understanding what stocks are you buying and why that stock at this point of time only. Also if one is thinking about increasing the exposure it would be better to stay with large caps as they would be able to weather any storm which might emerge due to any reason.
Tailwinds at the right time: 7 pharma stocks with an upside potential up to 37 %
It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case of pharmaceutical companies, tailwinds have emerged at a time when valuations of the overall market are expensive and it makes sense to look at pharma stocks as they tend to act as defensive stocks in volatile times with bearish bias. However they should not be clubbed together; each company has its own operating matrix. A company which has a strong domestic brand in the generic drugs segment, will not be getting impacted by what is happening in the US pharma market or what USFDA does. But yes, if it might be impacted by what happens in China.
Nifty healthcare index stocks; Staying bullish on select pharma and hospitals
While they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different. We take a look at what analysts are saying about different stocks from each of these segments. Stock Reports Plus, powered by Refinitiv, is a comprehensive research report that evaluates five key components of 4,000+ listed stocks - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores.
Stocks in the news: TCS, IndiGo, Tata Power, ZEE, AB Fashion and Max VIL
Rakesh Gangwal, co-founder of IndiGo, and his family are looking to sell a 2.8 per cent stake or 10.8 million shares in the budget carrier, through a block deal or roughly about Rs 1,996 crore.
Zydus gets nod to conduct Phase II clinical study in patients with CAPS in Australia
CAPS is a rare life-long auto-inflammatory condition, and is classified under orphan diseases. CAPS patients also experience multiple neurological complications like sensorineural hearing loss, migraine, headache, aseptic meningitis and myalgia.
Load More
